Episodios
-
In this special episode of PODTalk, we join our friends at Oribiotech on the OriSpotlight Podcast. Oribiotech CEO, Jason Foster, and G-CON's Vice President of Business Development and Sales Engineering, Dennis Powers, discuss the growth, transition and advancement of facilities in the cell and gene therapy sector of the biopharmaceutical industry.
-
In the biopharmaceutical industry, there has been a shift away from
on-site construction to prefabricated solutions. Peter Makowenskyj,
Director of Sales Engineering at G-CON Manufacturing Inc., recently
told Pharmaceutical Technology that speed to market and lower
total cost of ownership for facilities has accelerated this movement in the biopharma sector. He also discussed the strain that the COVID-19 pandemic has placed on operations across the industry and how the situation is creating a need for additional capacity. -
¿Faltan episodios?
-
In this episode, Dennis Powers, Vice President of Sales Engineering and Business Development for G-CON Manufacturing, discusses the POD effect on therapeutics with off-site manufacturing of modular/podular cleanrooms and G-CON's overall impact on the cell and gene therapy sector for manufacturing advanced therapies in prefabricated cleanrooms.
-
In this episode, experienced engineer and subject matter expert in aseptic facility design, Sandra Bachamp, discusses production planning, site selection and key things to consider when constructing cleanrooms for aseptic filling.
Don't forget to subscribe! New episodes released every 2 weeks.
-
In this episode, Director of Engineering and Project Management, Mark Taylor, discusses the project execution, challenges, achievements and success with a global pharmaceutical company whose goal was to scale up their manufacturing operations in the US and Europe for an approved CAR-T product. Specifically, the client was establishing internal lentivirus production capabilities, starting with a fast-track clinical facility at the one of their existing sites. In addition to the demand for clinical capabilities, a 200L commercial operation was also required. Both projects were schedule driven. The client chose G-CON’s POD technology for the clinical portion due to its higher probability of success in schedule driven projects.
New episodes are available every two weeks.
Visit our website at www.gconbio.com
